EQS-News
Carl Zeiss Meditec remains on growth course in fiscal year 2021/22 - Seite 2
The sales recovery continued in the strategic business unit Microsurgery and also exceeded market growth, with revenue increasing by +10.9% (adjusted for currency effects: +7.8%) to €434m (prior year: €391m). Orders received have recently developed disproportionately to revenue and increased by 28.6% (adjusted for currency effects: 25.7%), from €412m to €530m. In addition to robust demand, this is also attributable to the increase in production and delivery time in the equipment business due to strained supply chains, and in materials procurement.
Sustained positive growth rates in all reporting regions
Revenue in the EMEA[1]region increased by +6.1% (adjusted for currency effects: +6.5%), to €459m (prior year: €433m). The core markets Germany, France and Southern Europe and the United Kingdom continued to record solid growth.
Revenue in the Americas region increased by +8.4% (adjusted for currency effects: -0.1%) to €487m (prior year: €449m), mainly thanks to positive currency effects. After adjustment for currency effects, revenue in the USA developed at a roughly constant level compared with the prior year.
Once again, the APAC[2]region made the strongest contribution to growth. Revenue increased by 25.0% (adjusted for currency effects: +25.0%) to €957m (prior year: €765m). China and India had the highest growth rates.
Significant increase in earnings year-on-year
The operating result (earnings before interest and taxes: EBIT) increased to €397m in fiscal year 2021/22 (prior year: €374m). A more favorable product mix with a high proportion of recurring revenue of 46% (prior year: +41%) had a positive effect in this respect. This positive development is also attributable to stockpiling of consumables in the mid-double-digit millions range in the Chinese distribution channel. The majority of this took place in the second half of the fiscal year to provide for potential future lockdowns due to the Zero-COVID-Policy in China. In relation to revenue, an EBIT margin of 20.9% (prior year: 22.7%) was achieved in fiscal year 2021/22. Adjusted for special effects, this figure was 21.4% (prior year: 23.0%). Earnings per share increased to €3.29 (prior year: €2.64). Due to the successful fiscal year, shareholders are to receive an appropriate share of the profits. The Management Board therefore plans to propose a dividend of €1.10 (prior year: €0.90) to the Annual General Meeting.